Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 68

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 68
---
 Common Stock as-of the closing date of the Merger. The Exchange Ratio is calculated using the relative company valuations of each of TELO and TELI, as determined by Moore (as further described herein). It is expected that shareholders of TELI will receive one share of TELI Common Stock for each share of TELO Common Stock held (the “Merger Share Consideration”). The TELO Common Stock issued as the consideration will not be registered for trading under the Securities Act.

In addition to the Merger Share Consideration,
certain members of TELI collectively hold warrants to purchase a total of 14,250,000 TELI Common Stock (the “Warrants”).
The Warrants are exercisable upon FDA acceptance of an Investigational New Drug (IND) application for Telomir at $2.00 per share, for
a period of 10-years. At Closing, the Warrants will be converted to warrants to purchase Telomir Common Stock at similar terms as the
Warrants.

Absence of Contingent Consideration

There are no contingent value rights, earnouts, or milestone payments associated with the merger consideration

Exchange Procedures

Pursuant to the terms of the Merger Agreement, prior to or at the Closing, TELO shall designate its transfer agent, or a depository, bank or trust company reasonably acceptable to TELI to act as the exchange agent in connection with the Merger, or the Exchange Agent, and enter into an exchange agreement, in a form reasonably acceptable to TELI, for the payment of the Merger Consideration. Prior to or substantially concurrently with the Effective Time, TELO shall deposit or cause to be deposited with the Exchange Agent, for the benefit of the holders of TELI Common Stock for exchange in accordance with the terms and conditions of the Merger Agreement through the Exchange Agent, the full number of TELO Common Stock, which shall be in uncertificated book entry form, issuable as Merger Consideration.

Completion and Effectiveness of the Merger

The Merger will be completed as promptly as practicable after all of the conditions to Closing are satisfied or waived, including the approval of the stockholders of TELO and of TELI, unless earlier terminated in accordance with the terms of the Merger Agreement. For more information on termination rights, see the section titled “The Merger Agreement—Termination.” TELO and TELI cannot predict the exact timing of the Closing because it is subject to